AxoGen Inc
NASDAQ:AXGN
AxoGen Inc
Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. The company is headquartered in Alachua, Florida and currently employs 428 full-time employees. Its platform for peripheral nerve repair features a comprehensive portfolio of products, including Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, Avive Soft Tissue Membrane and Axotouch Two-Point Discriminator. Its products are used by surgeons during surgical interventions to repair a variety of physical nerve damage or transection throughout the body, which ranges from a simple laceration of a finger to a complex brachial plexus injury, as well as nerve injuries caused by dental, orthopedic, and other surgical procedures. Its Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix coaptation aid for tensionless repair of severed peripheral nerves. Its portfolio of products is available in the United States, Canada, Germany, Spain, South Korea, and several other countries.
Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. The company is headquartered in Alachua, Florida and currently employs 428 full-time employees. Its platform for peripheral nerve repair features a comprehensive portfolio of products, including Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, Avive Soft Tissue Membrane and Axotouch Two-Point Discriminator. Its products are used by surgeons during surgical interventions to repair a variety of physical nerve damage or transection throughout the body, which ranges from a simple laceration of a finger to a complex brachial plexus injury, as well as nerve injuries caused by dental, orthopedic, and other surgical procedures. Its Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix coaptation aid for tensionless repair of severed peripheral nerves. Its portfolio of products is available in the United States, Canada, Germany, Spain, South Korea, and several other countries.
Revenue Growth: AxoGen delivered Q3 revenue of $60.1 million, rising 23.5% year-over-year and 6% sequentially, driven by strong sales of Avance Nerve Graft and broad adoption across all target markets.
Guidance Raised: Full-year 2025 revenue growth guidance was increased to at least 19%, or $222.8 million, reflecting management confidence in ongoing momentum.
Profitability: The company posted net income of $0.7 million, reversing a loss from the prior year, and improved adjusted EBITDA margin to 15.4%.
Gross Margin Improvement: Gross margin grew to 76.6%, up from both prior year and prior quarter, benefiting from lower inventory write-offs and shipping costs.
BLA Progress: The Avance Nerve Graft Biologics License Application (BLA) review was extended, with FDA approval now expected by December 5, 2025; management is confident in securing approval and subsequent 12 years of exclusivity.
Coverage Expansion: Commercial coverage for nerve repair surpassed 64%, up sharply from last quarter, with 18.1 million additional covered lives year-to-date.
Case Stock Program Transition: Discontinuation of the Avance case stock program in Q3 boosted revenue by $1.6 million, but this was a one-time pickup and not expected to repeat in Q4.
Surgeon & Market Development: AxoGen continues to expand its sales force, meet training targets, and progress clinical research and market expansion, including in the prostate segment.
